CrystalGenomics Applies for Phase 3 Clinical Trial of Pancreatic Cancer Treatment
[Asia Economy Reporter Ji Yeon-jin] CrystalGenomics announced on the 30th that it has applied to the Ministry of Food and Drug Safety for approval of a Phase 3 clinical trial plan (IND) for a treatment for unresectable locally advanced or metastatic pancreatic cancer.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- KOSPI Turns Lower After Hitting 8,000 Points... Is Profit-Taking to Blame? [1-Minute Brief]
- "Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
This clinical trial targets patients with unresectable locally advanced or metastatic pancreatic cancer and aims to compare and evaluate the safety and efficacy of the current first-line standard therapy, FOLFIRINOX, versus a triple combination therapy of Ivaltinostat, Gemcitabine, and Erlotinib.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
